195 related articles for article (PubMed ID: 36450180)
1. Indian patients with human immunodeficiency virus infection have high prevalence but mild severity of non-alcoholic fatty liver disease.
De A; Duseja A; Badhala P; Taneja S; Sharma A; Arora S
Diabetes Metab Syndr; 2022 Dec; 16(12):102679. PubMed ID: 36450180
[TBL] [Abstract][Full Text] [Related]
2. Lean Indian patients with non-alcoholic fatty liver disease (NAFLD) have less metabolic risk factors but similar liver disease severity as non-lean patients with NAFLD.
De A; Mehta M; Singh P; Bhagat N; Mitra S; Das A; Duseja A
Int J Obes (Lond); 2023 Oct; 47(10):986-992. PubMed ID: 37474570
[TBL] [Abstract][Full Text] [Related]
3. Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV.
Milic J; Menozzi V; Schepis F; Malagoli A; Besutti G; Franconi I; Raimondi A; Carli F; Mussini C; Sebastiani G; Guaraldi G
AIDS; 2020 Nov; 34(13):1915-1921. PubMed ID: 33009010
[TBL] [Abstract][Full Text] [Related]
4. Transient Elastography in HIV Infected Patients with Liver Steatosis Identifies a High-Risk Group for Non-Alcoholic Steatohepatitis.
Pezzini MF; Cheinquer H; de Araujo A; Schmidt-Cerski CT; Sprinz E; Herz-Wolff F; Poeta J
Curr HIV Res; 2021; 19(4):311-316. PubMed ID: 33632105
[TBL] [Abstract][Full Text] [Related]
5. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population.
Petta S; Di Marco V; Pipitone RM; Grimaudo S; Buscemi C; Craxì A; Buscemi S
Liver Int; 2018 Nov; 38(11):2060-2068. PubMed ID: 29577560
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of serological biomarkers for detection of non-alcoholic fatty liver disease (NAFLD) and/or advanced liver fibrosis in people living with HIV.
Yanavich C; Pacheco AG; Cardoso SW; Nunes EP; Chaves U; Freitas G; Santos R; Morata M; Veloso VG; Grinsztejn B; Perazzo H
HIV Med; 2021 Jul; 22(6):445-456. PubMed ID: 33529485
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and dynamics of NAFLD-associated fibrosis in people living with HIV in Vienna from first presentation to last follow-up.
Schwarz C; Chromy D; Bauer D; Duong N; Schmidbauer VU; Schwarz M; Mandorfer M; Rieger A; Trauner M; Gschwantler M; Reiberger T
Wien Klin Wochenschr; 2023 Aug; 135(15-16):420-428. PubMed ID: 36576556
[TBL] [Abstract][Full Text] [Related]
8. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.
Tan EX; Lee JW; Jumat NH; Chan WK; Treeprasertsuk S; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Lesmana LA; Zheng KI; Zheng MH; Koh CJ; Ho KY; Goh KL; Wong VW; Dan YY
Metabolism; 2022 Jan; 126():154911. PubMed ID: 34648769
[TBL] [Abstract][Full Text] [Related]
9. Predictive factors associated with liver fibrosis and steatosis by transient elastography in patients with HIV mono-infection under long-term combined antiretroviral therapy.
Perazzo H; Cardoso SW; Yanavich C; Nunes EP; Morata M; Gorni N; da Silva PS; Cardoso C; Almeida C; Luz P; Veloso VG; Grinsztejn B
J Int AIDS Soc; 2018 Nov; 21(11):e25201. PubMed ID: 30394678
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV.
Michel M; Labenz C; Wahl A; Anders M; Armandi A; Huber Y; Galle PR; Sprinzl M; Schattenberg JM
AIDS; 2022 Oct; 36(12):1665-1674. PubMed ID: 35849074
[TBL] [Abstract][Full Text] [Related]
11. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients.
Huang Y; Gan Q; Lai R; Wang W; Guo S; Sheng Z; Chen L; Guo Q; Cai W; Wang H; Zhao G; Cao Z; Xie Q
Front Cell Infect Microbiol; 2021; 11():733348. PubMed ID: 35111690
[TBL] [Abstract][Full Text] [Related]
12. The impact of integrase inhibitors on steatosis and fibrosis biomarkers in persons with HIV naïve to antiretroviral therapy.
Fernandes SR; Leite AR; Lino R; Guimarães AR; Pineiro C; Serrão R; Freitas P
BMC Infect Dis; 2023 Aug; 23(1):553. PubMed ID: 37620821
[TBL] [Abstract][Full Text] [Related]
13. Overall and subgroup prevalence of non-alcoholic fatty liver disease and prevalence of advanced fibrosis in the United States: An updated national estimate in National Health and Nutrition Examination Survey (NHANES) 2011-2018.
Wang T; Xi Y; Raji A; Crutchlow M; Fernandes G; Engel SS; Zhang X
Ann Hepatol; 2024; 29(1):101154. PubMed ID: 37742743
[TBL] [Abstract][Full Text] [Related]
14. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
[TBL] [Abstract][Full Text] [Related]
17. Burden of fatty liver and hepatic fibrosis in persons with HIV: A diverse cross-sectional US multicenter study.
Gawrieh S; Lake JE; Debroy P; Sjoquist JA; Robison M; Tann M; Akisik F; Bhamidipalli SS; Saha CK; Zachary K; Robbins GK; Gupta SK; Chung RT; Chalasani N; Corey KE
Hepatology; 2023 Aug; 78(2):578-591. PubMed ID: 36805976
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients.
Vuille-Lessard É; Lebouché B; Lennox L; Routy JP; Costiniuk CT; Pexos C; Giannakis A; Szabo J; Klein MB; Sebastiani G
AIDS; 2016 Nov; 30(17):2635-2643. PubMed ID: 27603289
[TBL] [Abstract][Full Text] [Related]
19. Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV.
Lake JE; Taron J; Ribaudo HJ; Leon-Cruz J; Utay NS; Swaminathan S; Fitch KV; Kileel EM; Paradis K; Fulda ES; Ho KS; Luetkemeyer AF; Johnston CD; Zanni MV; Douglas PS; Grinspoon SK; Lu MT; Fichtenbaum CJ;
AIDS; 2023 Nov; 37(14):2149-2159. PubMed ID: 37503623
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis.
Kalligeros M; Vassilopoulos A; Shehadeh F; Vassilopoulos S; Lazaridou I; Mylonakis E; Promrat K; Wands JR
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1708-1722. PubMed ID: 36642292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
